|
시장보고서
상품코드
2077284
비알코올성 지방간염(NASH) 치료 및 진단 시장 : 치료별, 진단별, 지역별Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics, By Diagnostics, and By Geography - |
||||||
비알코올성 지방간염(NASH) 치료 및 진단 시장은 2026년에 304억 8,090만 달러 규모에 달할 것으로 추정되며, 2033년에 1,113억 3,850만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 20.3%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 304억 8,090만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026-2033년까지 예측 기간의 CAGR: | 20.30% | 2033년 시장 규모 예측: | 1,113억 3,850만 달러 |
비알코올성 지방간염(NASH)은 간 내의 과도한 지방세포로 인해 발생하는 간의 염증(지방간)입니다. 이러한 과도한 지방이 간 염증(부종)이나 섬유화(흉터 형성)를 유발함으로써 발병합니다. NASH는 '숨겨진 유행병'으로 여겨지고 있으며, 이에 따라 안전하고 효과적인 치료법 및 진단법에 대한 수요가 높아지고 있습니다.
시장 역학
NASH 환자 수의 증가, 당뇨병 및 비만 인구 증가, 안전하고 효과적인 NASH 치료 및 진단에 대한 수요 증가, 정부 및 비정부 기구의 지원 정책, 그리고 NAFLD/NASH에 대한 인식 제고가 예측 기간 동안 전 세계 비알코올성 지방간염(NASH) 치료 및 진단 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다.
예를 들어, 2022년 6월, Echosens와 Novo Nordisk A/S는 비알코올성 지방간염(NASH)의 조기 진단을 촉진하고, 환자, 의료 종사자 및 기타 이해관계자들 사이에서 이 질환에 대한 인식을 높이기 위한 제휴를 발표했습니다. 2018년 6월, Global Liver Institute는 NASH에 대한 인식을 높이고 이 질환을 예방하기 위해 사람들이 취할 수 있는 조치를 널리 알리기 위해 제1회 ‘국제 NASH의 날’을 제정했습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 비알코올성 지방간염(NASH) 치료 및 진단 시장의 주요 기업 개요을 발표하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- '세계 비알코올성 지방간염(NASH) 치료 및 진단 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 비알코올성 지방간염(NASH) 치료 및 진단 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 비알코올성 지방간염(NASH) 치료 및 진단 시장 : 치료별, 2021-2033년
제5장 세계의 비알코올성 지방간염(NASH) 치료 및 진단 시장 : 진단별, 2021-2033년
제6장 세계의 비알코올성 지방간염(NASH) 치료 및 진단 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSMNon-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market is estimated to be valued at USD 30,480.9 Mn in 2026 and is expected to reach USD 1,11,338.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 20.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 30,480.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 20.30% | 2033 Value Projection: | USD 1,11,338.5 Mn |
Non-alcoholic steatohepatitis (NASH) is inflammation of the liver caused by excess fat cells in it (fatty liver disease). It is caused when that extra fat turns into inflammation (swelling in the liver) and fibrosis (scarring) of the liver. NASH is a hidden epidemic, and thus, there is an increase demand for safe and effective therapeutics and diagnostics.
Market Dynamics:
Rise in NASH-affected population, increase in diabetic and obese population, increase in demand for safe and effective NASH therapeutics and diagnostics, favorable initiatives by government and non-government organizations, and increasing awareness about NAFLD/NASH are major factors expected to propel the growth of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.
For instance, in June 2022, Echosens and Novo Nordisk A/S announced a collaboration to advance the early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers, and other stakeholders. In June 2018, the first International NASH Day was launched by Global Liver Institute with the goal of raising awareness about NASH and the actions people can take to prevent the disease.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market.
Detailed Segmentation:
- Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics (Revenue, USD Mn, 2021 - 2033)
- Elafibranor
- Ocaliva
- Selonsertib
- Cenicriviroc
- Emricasan
- Other Therapeutics
- Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics (Revenue, USD Mn, 2021 - 2033)
- Imaging Techniques
- Diagnostic Tests
- Biopsy
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Novartis AG
- Allergan Plc.
- Viking Therapeutics
- Merck & Co.
- Zydus Cadila
- Novo Nordisk A/S
- GENFIT SA
- Gilead Sciences Inc.
- Galmed Pharmaceuticals
- Madrigal Pharmaceuticals
- Intercept Pharmaceuticals Inc.
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapeutics
- Market Snapshot, By Diagnostics
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in NASH-affected population worldwide
- Slow advancements in the therapeutic field
- Rise in demand for safe/effective therapeutics and diagnostics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Elafibranor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Ocaliva
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Selonsertib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Cenicriviroc
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Emricasan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Other Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
5. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Imaging Techniques
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Diagnostic Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
6. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Geography, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
7. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viking Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GENFIT SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Galmed Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Madrigal Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intercept Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
